linjc16/ctgov huggingface dataset:
Evaluation of the Frequency of Limitation of Activity in Patients With Persistent Asthma

Study Overview
=================
Brief Summary
-----------------
Evaluation of the frequency of limitation of activity, depending on gender and age-group, in patients with persistent asthma consulting a general practitioner

Official Title
-----------------
Evaluation of the Frequency of Limitation of Activity, Depending on Gender and Age-group, in Patients With Persistent Asthma Consulting a General Practitioner

Conditions
-----------------
Persistent Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: persistent asthma receiving long-term maintenance treatment with inhaled steroids (alone or in combination with other drugs) Exclusion Criteria: Patients with a diagnosis of COPD

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe the frequency of limitations of activities in patients with persistent asthma depending on gender and age-group. |  | Last 3 months / once | 
| To describe, depending on gender and age-group, the nature of the activities limited, the degree of limitation and the impact on the patient's daily life. |  | Once during only visit | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe the nature of the activities limited, the degree of limitation and the impact on the patient's daily life according to the level of asthma control |  | Once during only visit | 
| To describe, depending on gender and age-group, the activities that need to be specifically investigated in routine clinical practice due to their greater impact on the patient's quality of life, and which could indicate poorly controlled asthma |  | Once during only visit | 
| To describe the main characteristics and initial management for all patients of the survey |  | Once during only visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Limitations of activities, persistent asthma, general practitioner, frequency of limitations of activities, depending on gender and age-group
Efficacy of Adjustable Thermoplastic Oral Appliances in Patient With OSA

Study Overview
=================
Brief Summary
-----------------
Somnoguard, a titratable-thermoplastic oral appliances for the treatment of OSA, has been reported its safety and efficacy in Caucasians at least in the short-term. However, there has been no reports in Thai patients. The objectives of this study is to investigate its efficacy and safety in Thai patients with OSA.

Detailed Description
-----------------
Fifty patients with any severity of OSA will be recruited according to the indications for oral appliance therapy in the practice parameters of the American Academy of Sleep Medicine (AASM)2006.

Official Title
-----------------
The Efficacy of Adjustable Thermoplastic Oral Appliances in Thai Patient With OSA

Conditions
-----------------
OSA, Complication

Intervention / Treatment
-----------------
* Device: Somnoguard oral appliances


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years with OSA AHI > 5 Refused CPAP therapy Exclusion Criteria: Poor oral hygiene Untreated TMD Inadequate healthy teeth (< 6) Severe or unstable medical problems.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: treatment<br>patients treated with Somnoguard | Device: Somnoguard oral appliances<br>* wearing somnogaurd daily at bedtime<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Apnea-Hypopnea index |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with Adverse Events | Number of Participants with Adverse Events | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AHI, ESS, VAS, FOSQ, SF-36
Neurostructural Integration Technique for Fibromyalgia

Study Overview
=================
Brief Summary
-----------------
Fibromyalgia is a common cause of widespread musculoskeletal pain. The investigators have found that our patients seem to benefit from a soft tissue physical therapy called neurostructural integration therapy (NST). The purpose of this study was to compare NST to hydrotherapy which is already used to manage fibromyalgia symptoms.

Detailed Description
-----------------
Twenty female patients who met the American College of Rheumatology diagnostic criteria for the classification of FM were enrolled in the study. Patients were randomly allocated to receive either hydrotherapy or NST. Patient evaluations were performed at baseline, six weeks, three months, and six months. Primary outcome measures included the SF-36 quality of life questionnaire, the Fibromyalgia Impact Questionnaire and the Total Myalgic Score. Duration of morning stiffness and duration of weekly aerobic exercise as reported by the participants were secondary outcome measures. Statistics analysis was performed by standard parametric and non parametric methods.

Conditions
-----------------
Fibromyalgia

Intervention / Treatment
-----------------
* Other: NST
* Other: Hydrotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient who fulfills ACR diagnostic criteria for fibromyalgia Exclusion Criteria: Patients with established ischemic heart disease, uncontrolled hypertension or diabetes, hypothyroidism, severe depression

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NST<br>A form of physical therapy to relieve symptoms of fibromyalgia | Other: NST<br>* A form of physical therapy<br>|
| Active Comparator: Hydrotherapy<br>An alternate form of physical therapy to relieve symptoms of fibromyalgia | Other: Hydrotherapy<br> <br> * Other names: A form of physical therapy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fibromyalgia treatment, physical therapy, hydrotherapy
A Study of the Effect of Lenalidamide on Complex Regional Pain Syndrome Type 1

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if lenalidomide is a safe and effective treatment for complex regional pain syndrome type 1 (CRPS).

Official Title
-----------------
Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidamide in the Treatment of Complex Regional Pain Syndrome Type1

Conditions
-----------------
Complex Regional Pain Syndrome, Type 1

Intervention / Treatment
-----------------
* Drug: Lenalidamide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > or = to 18 years Signed consent form A diagnosis of CRPS type I for at least one-year duration with unilateral involvement of a distal limb CRPS pain intensity score at least 4 on an 11-point PI-NRS Measurable sural, median sensory, median motor and peroneal motor nerve conductions Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting the study drug. They must agree to use adequate contraceptive methods not including steroid-based contraceptives. They must also agree to have pregnancy tests every 4 weeks while on the study drug.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lenalidamide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| RPS Pain Intensity Numeric Rating Scale (PI-NRS): At least 30% reduction from baseline |  |  |
Evaluate the Utility of the ProLung China Test in the Diagnosis of Lung Cancer

Study Overview
=================
Brief Summary
-----------------
A Study to evaluate the utility of the ProLung China Test as an adjunct to CT scan in the diagnosis of lung cancer.

Detailed Description
-----------------
This Study will assess the stability of the ProLung China Test classification algorithm when used as an adjunct to CT scan. This Study will assess whether there are any potential safety concerns of the ProLung China Test when used to evaluate patients with a positive CT scan for lung cancer.

Official Title
-----------------
Evaluate the Utility of the ProLung China Test as Adjunctive to CT Scan in the Diagnosis of Lung Cancer

Conditions
-----------------
Solitary Pulmonary Nodule, Multiple Pulmonary Nodules

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is male or female, age 18 to 80. Subject has undergone CT scan of the lung(s) that indicates one or more nodules or lesions. Subject's pulmonary nodule or lesion is greater than 4mm and smaller than 50mm. Size is determined by the largest nodule or lesion dimension identified from CT imaging. Subject must be able to receive a ProLung China Test within 30 days of abnormal CT within 14 days prior to the tissue biopsy or surgical resection. Exclusion Criteria: Subject has an implanted electronic device in the chest. Subject receiving therapy for suspected chest infection such as fungal infection or tuberculosis. Subject with diagnosed malignancy other than lung cancer who has 2 or more suspicious pulmonary nodules. Subject has received an invasive medical or surgical procedure within the thoracic cavity within 30 days prior to the ProLung China Test or within the previous 14 days for a bronchoscopic procedure. Subject presents with an anomalous physical or anatomical condition that precludes ProLung China Test measurement. Subject will have undergone unusually strenuous exercise within 24 hours. Subject who has significant systemic diseases such as uncontrolled diabetes, advanced heart failure, or a recent myocardial infarction, or other medical condition such as severe morbid obesity that in the judgment of the Principal Investigator would make him/her unsuitable for the Study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and Efficacy of the ProLung China Test | Demonstrate safety and efficacy in the risk stratification of patients with pulmonary lesions identified by CT that are suspicious for lung cancer. | The ProLung China Test will be performed within 30 days of a CT Scan that identifies a lung lesion suspicious for lung cancer and evaluated once a patient diagnosis is obtained. |
Nasal Fentanyl And Renal Colic

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether nasal fentanyl is effective in the treatment of renal colic in adults in emergency department.

Conditions
-----------------
Acute Renal Colic

Intervention / Treatment
-----------------
* Drug: FENTANYL
* Drug: Ketorolac Tromethamine AND morphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patients were adults aged 18 to 65 years, presenting in ED with classical clinical symptoms of renal colic (sudden monolateral flank pain with inguinal irradiation) with a 10-cm visual analog scale (VAS) greater than or equal to 7 Exclusion Criteria: Were analgesia within 6 hours of arrival Allergy to opiates and NSAIDs Opiates abuse, known or suspected abdominal aortic dissection or aneurism, Presence of peritonitis Hemodynamic instability Pregnancy, breastfeeding, anticoagulant therapy. Patients with known renal, pulmonary, cardiac or hepatic failure, as well as those with renal transplantation, were also excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: NASAL FENTANYL,<br> | Drug: FENTANYL<br>* FENTANYL CITRATE, NASAL, 3 GAMMA/KG<br>|
| Active Comparator: KETOROLAC + MORPHINE<br> | Drug: Ketorolac Tromethamine AND morphine<br>* morphine 5 MG diluted in saline solution 100 ml followed by 2-ml ampoule of ketorolac 30 MG in saline solution 100 ml was infused:<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in visual analogue scale pain intensity score | This measure was obtained using a 10-cm with marked numbers visual analog scale (VAS score). | 30 and 60 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Use of rescue therapy at 30 minutes |  | 30 MINUTES | 
| The occurrence of adverse events |  | 60 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
analgesia, renal colic, ketorolac, nasal fentanyl, morphine., treatment of acute renal colic
Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients

Study Overview
=================
Brief Summary
-----------------
COVID-19 is an infectious disease caused by SARS-CoV2 virus. The objective of our study is to analyze the progression and the severity of COVID-19 in patients with RA. Indeed, few data are available on this subject, and this would allow us to improve management of COVID-19 in these potential at-risk patients.

Official Title
-----------------
Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients : ProCOVRA

Conditions
-----------------
Covid19, Rheumatoid Arthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - Confirmed COVID-19 diagnosis (positive PCR or serology) in RA patients or healthy controls. Exclusion criteria: Age under 18 years old Suspected COVID-19 diagnosis (typical symptoms without a positive PCR or serology)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospitalization rates for COVID-19 | Proportion of hospitalized patients in RA group or control group. From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery. | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Critical care transfer rate for COVID-19 and death due to COVID-19 | Proportion of patients transferred in critical care for COVID-19 or deaths due to COVID-19 From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery. | 1 day | 
| Pulmonary comorbidities, corticosteroids or DMARDs use | Type and severity of patients pulmonary comorbidities and treatment by corticosteroids or DMARDs in RA group From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery. | 1 day | 
| Age | Patients demographics From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery. | 1 day | 
| Number of Participants with co-morbidities | Patients comorbidities From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery. | 1 day | 
| Type of clinical presentation | Patients COVID-19 clinical presentation From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery. | 1 day | 
| Type of associated treatments | From first COVID-19 symtpoms, or first positive SARS-COV2 PCR result, to recovery. | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
DMARDs, Biotherapy
Fuji Type VII Sealant Versus Resin Based Sealant. A Clinical Trial

Study Overview
=================
Brief Summary
-----------------
Purpose: To evaluate the retention and caries preventive effect of the glass-ionomer fissure sealants and resin-based fissure sealant. Materials and Methods: Using a split mouth design ,a double blind randomized controlled clinical trial was conducted to compare the retention and the caries preventive effect of light cure resin base sealant (3M ESPE) and Glass ionomer sealant (FUJI). The study comprised of 120 government school children of 7-9 years age group. The glass-ionomer sealant and resin-based sealant were applied randomly on either side of the first mandibular permanent molars. They were recalled for assessment of sealant retention at intervals of 3, 6 and 12 months.

Official Title
-----------------
Fuji Type VII Sealants Versus Resin Based Sealants. A Clinical Trial

Conditions
-----------------
Dental Caries

Intervention / Treatment
-----------------
* Other: Application of the GIC based sealant
* Other: Resin based sealant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children with a fully erupted contra lateral permanent mandibular first molars with well-defined deep pits and fissures and molars free of mucosal tissue are included in the study. Exclusion Criteria: Molars with developmental anomalies, hypoplastic teeth were promptly excluded

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 9 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental arm<br>Fuji type VII is a GIC based sealant with an additional property of high fluoride release | Other: Application of the GIC based sealant<br>* Application of the GIC based sealant was carried out according to the manufacturer's instructions.<br>|
| Active Comparator: Resin based sealant<br>Helioseal F is a resin based sealant | Other: Resin based sealant<br>* Application of the resin based sealant on the occlusal surfaces was carried out as per the manufacturer s recommendations.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retention of the sealant | Retention of the sealants will be assessed by using the Simensons criteria | Baseline to 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Caries incidence |  | Baseline to 1 year |
CMV Intensive Care Units

Study Overview
=================
Brief Summary
-----------------
Prospectively assessment of CMV viremia by real-time polymerase chain reaction (PCR) in a broad cohort of consecutive immunocompetent adults admitted to a major heart surgery intensive care unit (MHS-ICU) with the goal of determining the epidemiology, risk factors, and clinical significance of CMV infection.

Official Title
-----------------
A Prospective Monitoring Study of Cytomegalovirus Infection in Immunocompetent Critical Heart Surgery Patients

Conditions
-----------------
CMV Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Agreeing to participate in the study Age of at least 18 years Admission to the MHS-ICU for at least 72 hours Exclusion Criteria: Inability to give informed consent Age younger than 18 years AIDS Pregnancy Organ or bone marrow transplant, receipt of immunosuppressive therapy including corticosteroids within 30 days, and cancer or hematologic malignancy treated with radiotherapy or chemotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| immunocompetent patients underwent heart surgery<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence number of participants with a positive CMV positive result |  | month 8 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| risk factors for CMV reactivation |  | month 8 | 
| mortality by day 30 | composite endpoint. hospitalization or death by day 30 | month 8 | 
| prolonged hospitalization . More than 30 days |  | month 8 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cytomegalovirus, critical patient, ICU, immunocompetent, clinical suspicion, risk factors